{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:22:02Z","timestamp":1790173322993,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007480","name":"Universidad de Castilla-La Mancha","doi-asserted-by":"publisher","award":["2022-PROD-20657"],"award-info":[{"award-number":["2022-PROD-20657"]}],"id":[{"id":"10.13039\/501100007480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["FPU21\/06866"],"award-info":[{"award-number":["FPU21\/06866"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40272-024-00655-5","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T08:02:22Z","timestamp":1727424142000},"page":"695-707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A Systematic Review"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1154-8752","authenticated-orcid":false,"given":"Carlos","family":"Pascual-Morena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7944-1065","authenticated-orcid":false,"given":"Maribel","family":"Lucer\u00f3n-Lucas-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7835-6953","authenticated-orcid":false,"given":"Irene","family":"Mart\u00ednez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6907-7872","authenticated-orcid":false,"given":"Eva","family":"Rodr\u00edguez-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3470-1724","authenticated-orcid":false,"given":"Silvana","family":"Pati\u00f1o-Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8981-4331","authenticated-orcid":false,"given":"Irene","family":"Sequ\u00ed-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"655_CR1","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","volume":"2","author":"F Muntoni","year":"2003","unstructured":"Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2003;2:731\u201340.","journal-title":"Lancet Neurol"},{"key":"655_CR2","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.nmd.2014.03.008","volume":"24","author":"JK Mah","year":"2014","unstructured":"Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 2014;24:482\u201391.","journal-title":"Neuromuscul Disord"},{"key":"655_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"CL Bladen","year":"2015","unstructured":"Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat. 2015;36:395\u2013402.","journal-title":"Hum Mutat"},{"key":"655_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17:211\u20132.","journal-title":"Lancet Neurol"},{"issue":"4","key":"655_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17(4):347\u201361.","journal-title":"Lancet Neurol"},{"key":"655_CR6","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1016\/j.apmr.2022.05.015","volume":"103","author":"C Pascual-Morena","year":"2022","unstructured":"Pascual-Morena C, Cavero-Redondo I, Reina-Guti\u00e9rrez S, Saz-Lara A, L\u00f3pez-Gil JF, Mart\u00ednez-Vizca\u00edno V. Prevalence of neuropsychiatric disorders in Duchenne and Becker muscular dystrophies: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2022;103:2444\u201353.","journal-title":"Arch Phys Med Rehabil"},{"key":"655_CR7","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/dmcn.15481","volume":"65","author":"C Pascual-Morena","year":"2022","unstructured":"Pascual-Morena C, Cavero-Redondo I, \u00c1lvarez-Bueno C, Jim\u00e9nez-L\u00f3pez E, Saz-Lara A, Mart\u00ednez-Garc\u00eda I, et al. Global prevalence of intellectual developmental disorder in dystrophinopathies: a systematic review and meta-analysis. Dev Med Child Neurol. 2022;65:734\u201344.","journal-title":"Dev Med Child Neurol"},{"key":"655_CR8","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/ppul.25261","volume":"56","author":"J Kipke","year":"2021","unstructured":"Kipke J, Birnkrant DJ, Jin JB, Aneja A, Bahler RC. A systematic review of pharmacologic therapies for the cardiomyopathy of Duchenne muscular dystrophy. Pediatr Pulmonol. 2021;56:782\u201395.","journal-title":"Pediatr Pulmonol"},{"key":"655_CR9","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/acn3.51149","volume":"7","author":"C Pascual-Morena","year":"2020","unstructured":"Pascual-Morena C, Cavero-Redondo I, \u00c1lvarez-Bueno C, Mesas AE, Pozuelo-Carrascosa D, Mart\u00ednez-Vizca\u00edno V. Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: a systematic review. Ann Clin Transl Neurol. 2020;7:1738\u201352.","journal-title":"Ann Clin Transl Neurol"},{"key":"655_CR10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391:451\u201361.","journal-title":"Lancet"},{"key":"655_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3233\/JND-210776","volume":"9","author":"WD Biggar","year":"2022","unstructured":"Biggar WD, Skalsky A, McDonald CM. Comparing deflazacort and prednisone in Duchenne muscular dystrophy. J Neuromuscul Dis. 2022;9:463\u201376.","journal-title":"J Neuromuscul Dis."},{"key":"655_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/hmg\/ddad173","volume":"33","author":"G Liu","year":"2024","unstructured":"Liu G, Lipari P, Mollin A, Jung S, Teplova I, Li W, et al. Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models. Hum Mol Genet. 2024;33:211\u201323.","journal-title":"Hum Mol Genet"},{"key":"655_CR13","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.3233\/JND-230161","volume":"10","author":"MD Grounds","year":"2023","unstructured":"Grounds MD, Lloyd EM. Considering the promise of vamorolone for treating Duchenne muscular dystrophy. J Neuromuscul Dis. 2023;10:1013\u201330.","journal-title":"J Neuromuscul Dis."},{"key":"655_CR14","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/emmm.201302621","volume":"5","author":"CR Heier","year":"2013","unstructured":"Heier CR, Damsker JM, Yu Q, Dillingham BC, Huynh T, Van der Meulen JH, et al. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med. 2013;5:1569\u201385.","journal-title":"EMBO Mol Med"},{"key":"655_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40265-023-01986-2","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ. Vamorolone: first approval. Drugs. 2024;84:111\u20137.","journal-title":"Drugs"},{"key":"655_CR16","doi-asserted-by":"publisher","first-page":"1107474","DOI":"10.3389\/fneur.2023.1107474","volume":"14","author":"RH Elhalag","year":"2023","unstructured":"Elhalag RH, Motawea KR, Talat NE, Rouzan SS, Shah J. Efficacy of vamorolone in treatment of Duchene muscle dystrophy: a meta-analysis. Front Neurol. 2023;14:1107474.","journal-title":"Front Neurol"},{"key":"655_CR17","doi-asserted-by":"crossref","unstructured":"Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions: Cochrane Book Series. John Wiley and Sons; 2008. Available from: https:\/\/research.monash.edu\/en\/publications\/cochrane-handbook-for-systematic-reviews-of-interventions-cochran. [Accessed 28 Oct 2020].","DOI":"10.1002\/9780470712184"},{"key":"655_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6: e1000097.","journal-title":"PLoS Med"},{"key":"655_CR19","unstructured":"Eldridge S, Campbell MK, Campbell MJ, Drahota-Towns A, Giraudeau B, Higgins JPT, et al. Revised Cochrane risk of bias tool for randomized trials (RoB 2.0): additional considerations for cluster-randomized trials. 2016. Available from: https:\/\/researchportal.port.ac.uk\/en\/publications\/revised-cochrane-risk-of-bias-tool-for-randomized-trials-rob-20-a. [Accessed 20 Sep 2024]."},{"key":"655_CR20","unstructured":"NHLBI, NIH. Study quality assessment tools. Available from: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools. [Accessed 17 Apr 2021]."},{"key":"655_CR21","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.phrs.2018.09.007","volume":"136","author":"LS Conklin","year":"2018","unstructured":"Conklin LS, Damsker JM, Hoffman EP, Jusko WJ, Mavroudis PD, Schwartz BD, et al. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacol Res. 2018;136:140\u201350.","journal-title":"Pharmacol Res"},{"key":"655_CR22","doi-asserted-by":"publisher","first-page":"e1312","DOI":"10.1212\/WNL.0000000000008168","volume":"93","author":"EP Hoffman","year":"2019","unstructured":"Hoffman EP, Schwartz BD, Mengle-Gaw LJ, Smith EC, Castro D, Mah JK, et al. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology. 2019;93:e1312\u201323.","journal-title":"Neurology"},{"key":"655_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003222","volume":"17","author":"EC Smith","year":"2020","unstructured":"Smith EC, Conklin LS, Hoffman EP, Clemens PR, Mah JK, Finkel RS, et al. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: an 18-month interim analysis of a non-randomized open-label extension study. PLoS Med. 2020;17: e1003222.","journal-title":"PLoS Med"},{"key":"655_CR24","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","volume":"79","author":"M Guglieri","year":"2022","unstructured":"Guglieri M, Clemens PR, Perlman SJ, Smith EC, Horrocks I, Finkel RS, et al. Efficacy and safety of vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial. JAMA Neurol. 2022;79:1005\u201314.","journal-title":"JAMA Neurol"},{"key":"655_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44178","volume":"5","author":"JK Mah","year":"2022","unstructured":"Mah JK, Clemens PR, Guglieri M, Smith EC, Finkel RS, Tulinius M, et al. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: a 30-month nonrandomized controlled open-label extension trial. JAMA Netw Open. 2022;5: e2144178.","journal-title":"JAMA Netw Open"},{"key":"655_CR26","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208112","volume":"102","author":"UJ Dang","year":"2024","unstructured":"Dang UJ, Damsker JM, Guglieri M, Clemens PR, Perlman SJ, Smith EC, et al. Efficacy and safety of vamorolone over 48 weeks in boys with Duchenne muscular dystrophy: a randomized controlled trial. Neurology. 2024;102: e208112.","journal-title":"Neurology"},{"key":"655_CR27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/mus.23905","volume":"48","author":"CM Mcdonald","year":"2013","unstructured":"Mcdonald CM, Henricson EK, Abresch RT, Florence J, Eagle M, Gappmaier E, et al. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve. 2013;48:357\u201368.","journal-title":"Muscle Nerve"},{"key":"655_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0283669","volume":"18","author":"V Ayyar Gupta","year":"2023","unstructured":"Ayyar Gupta V, Pitchforth JM, Domingos J, Ridout D, Iodice M, Rye C, et al. Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy. PLoS\u00a0One. 2023;18: e0283669.","journal-title":"PLoS\u00a0One"},{"key":"655_CR29","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.nmd.2010.06.014","volume":"20","author":"E Mazzone","year":"2010","unstructured":"Mazzone E, Martinelli D, Berardinelli A, Messina S, D\u2019Amico A, Vasco G, et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2010;20:712\u20136.","journal-title":"Neuromuscul Disord"},{"key":"655_CR30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/mus.23902","volume":"48","author":"CM Mcdonald","year":"2013","unstructured":"Mcdonald CM, Henricson EK, Abresch RT, Florence JM, Eagle M, Gappmaier E, et al. THE 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve. 2013;48:343\u201356.","journal-title":"Muscle Nerve"},{"key":"655_CR31","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/psp4.12220","volume":"6","author":"L Hamuro","year":"2017","unstructured":"Hamuro L, Chan P, Tirucherai G, AbuTarif M. Developing a natural history progression model for Duchenne muscular dystrophy using the six-minute walk test. CPT Pharmacometrics Syst Pharmacol. 2017;6:596\u2013603.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"655_CR32","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/dmcn.15176","volume":"64","author":"AA Zambon","year":"2022","unstructured":"Zambon AA, Gupta VA, Ridout D, Manzur AY, Baranello G, Trucco F, et al. Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy. Dev Med Child Neurol. 2022;64:979\u201388.","journal-title":"Dev Med Child Neurol"},{"key":"655_CR33","doi-asserted-by":"crossref","unstructured":"American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111\u20137.","DOI":"10.1164\/ajrccm.166.1.at1102"},{"key":"655_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160195","volume":"11","author":"E Mercuri","year":"2016","unstructured":"Mercuri E, Coratti G, Messina S, Ricotti V, Baranello G, D\u2019Amico A, et al. Revised North Star Ambulatory Assessment for young boys with Duchenne muscular dystrophy. PLoS\u00a0One. 2016;11: e0160195.","journal-title":"PLoS\u00a0One"},{"key":"655_CR35","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3233\/JND-210646","volume":"8","author":"T Duong","year":"2021","unstructured":"Duong T, Canbek J, Birkmeier M, Nelson L, Siener C, Fernandez-Fernandez A, et al. The minimal clinical important difference (MCID) in annual rate of change of timed function tests in boys with DMD. J Neuromuscul Dis. 2021;8:939\u201348.","journal-title":"J Neuromuscul Dis."},{"key":"655_CR36","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMcp1012926","volume":"365","author":"RS Weinstein","year":"2011","unstructured":"Weinstein RS. Clinical practice: glucocorticoid-induced bone disease. N Engl J Med. 2011;365:62\u201370.","journal-title":"N Engl J Med"},{"key":"655_CR37","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s001980070116","volume":"11","author":"P Szulc","year":"2000","unstructured":"Szulc P, Seeman E, Delmas PD. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int. 2000;11:281\u201394.","journal-title":"Osteoporos Int"},{"key":"655_CR38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s002280050160","volume":"51","author":"G Babadjanova","year":"1996","unstructured":"Babadjanova G, Allolio B, Vollmer M, Reincke M, Schulte HM. Comparison of the pharmacodynamic effects of deflazacort and prednisolone in healthy subjects. Eur J Clin Pharmacol. 1996;51:53\u20137.","journal-title":"Eur J Clin Pharmacol"},{"key":"655_CR39","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","volume":"87","author":"RC Griggs","year":"2016","unstructured":"Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87:2123\u201331.","journal-title":"Neurology"},{"key":"655_CR40","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","volume":"85","author":"L Bello","year":"2015","unstructured":"Bello L, Gordish-Dressman H, Morgenroth LP, Henricson EK, Duong T, Hoffman EP, et al. Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology. 2015;85:1048\u201355.","journal-title":"Neurology"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-024-00655-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-024-00655-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-024-00655-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T15:05:12Z","timestamp":1730127912000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-024-00655-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["655"],"URL":"https:\/\/doi.org\/10.1007\/s40272-024-00655-5","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"9 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is supported by the University of Castilla - La Mancha. In addition, Irene Mart\u00ednez-Garc\u00eda was supported by the Ministry of Science, Innovation and Universities [FPU21\/06866] and ML-L-T by the University of Castilla - La Mancha [2022-PROD-20657].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interests\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data are available upon reasonable request to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualisation: CP-M; methodology: CP-M and IS-D; data curation and investigation: CP-M and IS-D; formal analysis: CP-M, ML-L-T, IM-G and ER-G; validation and visualisation: ML-L-T, IM-G and SP-C; writing (original draft preparation): CP-M and IS-D; writing (review and editing): all authors; supervision: IS-D; funding acquisition: CP-M and IS-D; project administration: CP-M and IS-D. All authors have read and agreed to the published version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}